Last reviewed · How we verify
DUVAX 200 µg — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
DUVAX 200 µg (DUVAX 200 µg) — Nuravax, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DUVAX 200 µg TARGET | DUVAX 200 µg | Nuravax, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DUVAX 200 µg CI watch — RSS
- DUVAX 200 µg CI watch — Atom
- DUVAX 200 µg CI watch — JSON
- DUVAX 200 µg alone — RSS
Cite this brief
Drug Landscape (2026). DUVAX 200 µg — Competitive Intelligence Brief. https://druglandscape.com/ci/duvax-200-g. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing